Vancouver, British Columbia / January 28, 2021 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), has provided the following update on projects in progress.
APTI is pleased to report that its ongoing projects are moving forward as planned.
Our previously announced collaboration with Dr. Brian Zeglis at the City University of New York to test APTI’s site specific conjugation technology in the rapidly growing field of antibody radioisotope conjugates (ARCs) has progressed through the pilot stage and the main study is planned for the coming weeks. As previously reported, ARC constructs using APTI conjugation technology showed superior homogeneity, consistent payload to antibody ratio, high stability and maintained antibody binding affinity leading into the pilot. In the pilot stage, a limited number of mice were administered ARCs and underwent PET imaging and biodistribution. The main study is not designed to show statistically significant differences between constructs, but rather demonstrate how APT site-selective technology performs with a standard reference. As such, non-statistical differences are expected, but it is widely accepted that siteselective conjugates (a major advantage of using APTI technology) behave better in more complex models and have significant advantages in development. Despite these expectations, the preliminary results strongly favor APTI’s constructs with numerically higher tumor uptake as well as greater ratio between tumor and non-target organs.
APTI previously reported that its scientists have invented new technologies to improve characteristics of linkers and toxins and lead to safer and more efficacious antibody-drug conjugates (ADCs). These new inventions will complement APT’s existing conjugation technology and provide suite of technologies for off-the-shelf ADC generation. We believe this will both greatly improve our attractiveness to potential collaborators looking to develop ADCs and improve the performance of ADCs that APT plans to develop in a ‘biobetter’ approach. Synthesis of the first linker inventions is in progress. Once complete, APTI will perform preliminary testing in vitro prior to constructing variants to optimize characteristics and proceed with in vivo studies. Experience with the first set of inventions will lead to accelerated development of the subsequent inventions.
Dr. Benjamin Krantz, Director and incoming CEO of APTI commented “APTI is hitting the ground running in 2021 with promising data from the pilot portion of our radioimmunoconjugate collaboration with Dr. Zeglis and progress on the synthesis of our improved linker/toxin inventions. Together these projects continue to support APTs approach having generated leading conjugation technology that is candidate ready and now improving the remaining elements that create ADCs. The collaboration with Dr. Zeglis opens up possibilities in the field of ARCs and I look forward to seeing the main study results.”
Paul Woodward, CEO of the Company stated We are excited by the prospects inherent in APTI’s collaboration with Dr. Zeglis; ARCs are a commercially active area of biotechnology and Dr. Zeglis’ work is providing yet more valuable data that is consistent with the superiority of APTI’s conjugation technology which will be applicable to both ARCs and ADCs. Best in class conjugation technology is a valuable technology, however, it is but one of four vital elements of ADCs; the inventions that APTI is working on now will provide APTI with “universal” versions of three of the four components of ADCs (the linker, the toxin, and the conjugation chemistry). These technologies will make development of optimized proprietary ADCs faster and less expensive by allowing APTI to integrate a wholly owned full compatible suite of ADC technology to any antibody.
ABOUT THE COMPANY:
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., has invented proprietary protein conjugation technology which enables the development of superior antibody-drug conjugates through improved site-specific labeling, drug-antibody ratio control and enabling of combination payloads. The technology has compelling pre-clinical data demonstrating improved homogeneity and increased in-vivo potency relative to current state of the art linker technology. The Company believes that the technology will enable the development of safer and more potent antibody-drug conjugate therapeutics and is pursuing licensing and partnership opportunities to advance development and create shareholder value.
FOR FURTHER INFORMATION PLEASE CONTACT:
Advanced Proteome Therapeutics Corporation
President and CEO
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “intends”, “anticipates”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are risks detailed from time to time in the filings made by the Company with securities regulators.
Readers are cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that any forward-looking statement will materialize, and readers should not place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.